Wayne L. Furman, MD

Articles by Wayne L. Furman, MD

Extending Principles Learned in Model Systems to Clinical Trials Design

ByPeter J. Houghton, PhD,Joyce Thompson, MD,Victor M. Santana, MD,Wayne L. Furman, MD,Henry S. Friedman, MD

August 1st 1998

Clinical results with irinotecan (CPT-11 [Camptosar]) and other camptothecin derivatives in various cancers, although encouraging, have fallen short of the expectations predicted by preclinical models. One proposed

Latest Updated Articles

Extending Principles Learned in Model Systems to Clinical Trials Design
Published: August 1st 1998 | Updated:

Wayne L. Furman, MD

Articles by Wayne L. Furman, MD

Extending Principles Learned in Model Systems to Clinical Trials Design

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Ziftomenib in R/R NPM1-Mutated Acute Myeloid Leukemia

Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab

FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer

Novel Anti-CD5 Therapy Earns FDA RMAT Designation in T-Cell Lymphoma

Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC